Skip to main content
ANIP
NASDAQ Life Sciences

ANI Pharmaceuticals Posts Record Q2 Revenue of $266M and Reaffirms Full-Year Outlook

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$77.5
Mkt Cap
$1.879B
52W Low
$64.99
52W High
$99.5
52W Position info
19% above low
Off High info
22% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

ANIP sits 19% above its 52-week low of $64.99 on elevated volume (2.1× avg).

Summary

Record Q2 2026 revenue of $266 million, up 25.9% year-over-year, was accompanied by a reaffirmed full-year guidance. Cortrophin Gel revenue grew 43.5% to $117.1 million, and early momentum from the gout expansion is positive.


Key Events · Earnings and Guidance · ANIP

  • Record Q2 Revenue of $266M

    Total net revenues climbed 25.9% year-over-year to $266.0 million, fueled by Cortrophin Gel (up 43.5% to $117.1M) and Generics (up 9.7% to $99.1M).

  • Adjusted EBITDA Jumps 32.4%

    Adjusted non-GAAP EBITDA reached $71.6 million, a 32.4% increase, with adjusted diluted EPS of $2.21 compared to $1.80 a year ago.

  • Full-Year Guidance Reaffirmed

    Management reiterated 2026 total revenue guidance of $1,080–$1,140 million and adjusted EBITDA of $285–$300 million, while modestly lowering Cortrophin Gel revenue guidance to $520–$540 million (from $540–$575M).

  • Gout Expansion Fully Operational

    The expanded Rare Disease sales force targeting acute gouty arthritis flares was fully deployed by the end of June; early indicators show over 95% of reps generating multiple new patient cases.


Analysis · ANIP · Life Sciences

A strong quarter was driven by 25.9% revenue growth, anchored by the lead rare disease drug Cortrophin Gel, which surged 43.5%. Reaffirming the full-year outlook underscores management's confidence in the ongoing gout expansion and pipeline progress. The modest trim to Cortrophin Gel guidance—now $520–$540M—reflects a more conservative ramp but still implies 50–55% growth. With $360M in cash and a new $100M buyback authorization, the balance sheet comfortably supports both investment and shareholder returns.

How filings like this one have moved

In the 30 days to Nov 8, 2026, 36.5% of the 3015 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANIP was trading at $77.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $64.99 to $99.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANIP - Latest Insights

ANIP
Nov 05, 2026, 5:13 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $69.00
Real-time Price: $67.41 info
Change: -$1.59 (-2%) info
Market Cap: $1.548B info
ANIP
Nov 05, 2026, 6:58 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $75.00
Real-time Price: $67.41 info
Change: -$7.59 (-10%) info
Market Cap: $1.548B info
ANIP
Nov 05, 2026, 6:56 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.72
Real-time Price: $67.41 info
Change: -$4.31 (-6%) info
Market Cap: $1.548B info
ANIP
Nov 05, 2026, 6:51 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $72.00
Real-time Price: $67.41 info
Change: -$4.59 (-6%) info
Market Cap: $1.548B info
ANIP
Nov 05, 2026, 1:33 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $72.00
Real-time Price: $67.41 info
Change: -$4.59 (-6%) info
Market Cap: $1.548B info